ASH Clinical News ACN_4.3_FULL-ISSUE-DIGITAL | Page 40

Literature Scan
• 97.7 % for low vs . 93.8 % for lowintermediate ( HR = 1.02 ; 90 % CI 0.34-3.27 ; p = 0.999 )
Secondary outcomes , including rates of overall response ( 84 / 86 [ 98 %] and 86 / 90 [ 96 %]), complete response ( 42 / 86 [ 49 %] and 50 / 90 [ 56 %]), and partial response ( 42 / 86 [ 49 %] and 36 / 90 [ 40 %]), all were similar between the R-CHOP and VR-CHOP treatment groups . Median duration of response was not met in either group , but rates of response at two years were similar ( 82.7 % and 84.0 %, respectively .
“ The similarity of these rates for R-CHOP and VR-CHOP suggest that prolonged follow-up of patients on this trial is unlikely to reveal a difference ,” the authors noted . “ A potential reason for the lack of benefit with VR-CHOP was that only two doses of bortezomib were given per 21-day cycle ,” they wrote .
Another possible explanation was the observed discrepancies in the Hans algorithm used for DLBCL subtype classification , suggesting “ that the Hans algorithm may be suboptimal for this purpose ,” the researchers wrote , noting this as a limitation .
Millennium Pharmaceuticals , a subsidiary of Takeda , supported the study .
The authors report financial relationships with Celgene , AbbVie , Juno Therapeutics , Compass Oncology , TG Therapeutics , Gilead Sciences , Seattle Genetics , Acerta Pharma , CTI BioPharma , Genentech , Janssen Oncology , Pharmacyclics , Novartis , and GlaxoSmithKline .

Momelotinib Trial in Myelofibrosis Fails to Meet Primary Endpoint

The Janus kinase ( JAK ) inhibitor ruxolitinib is the only treatment approved by the U . S . Food and Drug Administration for patients with myelofibrosis ( MF ), and patients who experience disease progression or inadequate response to this treatment have limited options .
In the phase III SIMPLIFY 2 study ,

Shire provides a broad range of hematology products

Claire N . Harrison , DM , of the Guy ’ s and St . Thomas ’ National Health Service Foundation Trust in London , and co-authors compared momelotinib , a JAK1 and JAK2
REFERENCE
Leonard JP , Kolibaba KS , Reeves JA , et al . Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma . J Clin Oncol . 2017 ; 35:3538-46 .
38 ASH Clinical News
© 2017 Shire US Inc ., Lexington , MA 02421 . All rights reserved . 1-800-828-2088 SHIRE and the Shire Logo are registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates . ADVATE , ADYNOVATE , FEIBA , OBIZUR , RIXUBIS , and VONVENDI are registered trademarks of Baxalta Incorporated , a wholly owned , indirect subsidiary of Shire plc . S33331 11 / 17